U.S. Machinery Stock News

Li Auto (LI) is back in focus after HSBC cut the stock to Hold and slashed earnings forecasts, citing a major recall, delivery bottlenecks, and weaker sales as mounting operational headaches. See our latest analysis for Li Auto. Those concerns have already been reflected in the tape, with Li Auto’s share price sliding to around $17.0 and posting a steep 90 day share price return of roughly negative 34 percent. The 1 year total shareholder return of about negative 28 percent suggests sentiment...

If you are wondering whether American Airlines Group is a bargain or a value trap at current levels, this article will walk you through what the numbers are really saying about the stock. After a choppy stretch, the share price has climbed about 5.5% over the last week and 28.0% over the past month, even though it is still down 7.2% year to date and 6.5% over the last year. Recent headlines have focused on the airline sector's shifting demand outlook and ongoing efforts to manage costs and...

Ameren Corporation has announced that Jamie L. Engstrom, currently senior vice president and global chief information officer at Caterpillar, was elected to its board of directors effective January 1, 2026, with roles on the Audit and Risk Committee and the Cybersecurity and Digital Technology Committee. By adding a board member with deep experience in information systems and cybersecurity, Ameren is underscoring governance focus on digital resilience and technology-driven reliability across...

Wondering if EQT at around $53.87 is still a smart way to play natural gas, or if most of the upside has already been priced in? This breakdown will walk through what the market might be missing. Despite a choppy near term, with the stock down 3.1% over the last week and 8.5% over the last month, EQT is still up 13.8% year to date and 26.8% over the past year, with multi-year gains above 300% painting a much stronger long term picture. Those swings have come against a backdrop of shifting...

Tandem Diabetes Care (TNDM) just rolled out its t:slim mobile app in Canada for both Android and iOS users, extending smartphone control to t:slim X2 pump wearers and adding another catalyst to an already improving story. See our latest analysis for Tandem Diabetes Care. The Canadian launch of the t:slim app slots into a broader rebound story, with a 30 day share price return of 17.77 percent and a powerful 90 day share price return of 75.58 percent, even though the one year total shareholder...

Byrna Technologies has reported preliminary guidance for its fiscal fourth quarter and full year 2025, expecting US$35.1 million in quarterly revenue and US$118.0 million for the year, reflecting strong dealer, chain store, direct-to-consumer, and international performance compared with 2024. The company’s decision to ring the Nasdaq Opening Bell in December 2025 underscores how its expanding retail footprint, successful Byrna CL launch, and heightened brand visibility are becoming central...

If you have been wondering whether Waste Connections at around $175 a share is still worth buying, you are not alone. This stock often flies under the radar despite behaving like a quiet compounder. Over the past week the stock is up about 1.5%, roughly 0.3% over the last month, and it is sitting on a 3.1% gain year to date, with longer term returns of 34.2% over three years and 78.9% over five years that hint at a steady growth story rather than a flashy momentum trade. Much of the recent...

If you are wondering whether V.F is a beaten-down bargain or a value trap at this point in the cycle, you are not alone. That is exactly what this breakdown is here to unpack. After a long slide, including a -73.7% return over 5 years and -14.5% over the last year, the stock has shown some life with a sharp 26.9% jump over the past month, despite being down -13.6% year to date and -5.3% in the last week. That recent rebound has come as investors focus on V.F's ongoing portfolio reshaping and...

Amcor (NYSE:AMCR) just confirmed it will move ahead with a 1 for 5 reverse stock split in mid January 2026, a structural shift that will immediately reshape the share count and optics. See our latest analysis for Amcor. That move lands after a choppy stretch where the 1 year total shareholder return is down 6.6 percent, and the year to date share price return of negative 11.3 percent signals fading momentum despite underlying earnings growth. If this shake up has you rethinking where to look...

BeOne Medicines (ONC) is back in focus after the FDA granted Fast Track Designation to its liver cancer bispecific BGB-B2033 and accepted sonrotoclax for Priority Review, underscoring real momentum across its oncology pipeline. See our latest analysis for BeOne Medicines. Those back to back FDA milestones have arrived after a choppy few weeks, with a 30 day share price return of minus 10.7 percent but a powerful year to date share price gain of 71.8 percent. This suggests underlying momentum...

If you are wondering whether Redwire at around $8 is a bruised bargain or a value trap, you are not alone. That is exactly what we are going to unpack here. The stock has bounced sharply in the short term, up 9.7% over the last week and 46.0% over the last month, but it is still down 53.1% year to date and 42.4% over the past year, even after a huge 316.7% gain over three years. Those kinds of swings have come alongside a steady stream of space infrastructure contract wins and strategic...

If you have been wondering whether Herbalife at around $13.99 is a bargain or a value trap, you are not alone. This breakdown is designed to help you cut through the noise. The stock has been on a wild ride, dropping about 5.1% over the last week but still up 51.7% over the past month and 109.4% year to date, with a 115.9% gain over the last year despite a 71.1% slide over five years. Recent coverage has highlighted how investors are reassessing Herbalife's long term prospects in light of...

In recent days, SES AI Corporation and Korea-based Top Material announced plans to collaborate on expanding lithium-metal and lithium-ion cell manufacturing capacity in Korea for drones and urban air mobility, aiming to build an NDAA-compliant, cost-efficient supply chain under a non-binding agreement targeting a definitive deal by early 2026. SES AI also outlined plans to nearly triple output at its Chungju plant to around 1 million AI-enabled pouch cells annually, highlighting how drones...

The story around SPS Commerce (SPSC) shifted quickly after activist investor Anson disclosed a stake and began pushing for a potential sale, just months after the Carbon6 deal ran into new Amazon marketplace headwinds. See our latest analysis for SPS Commerce. The activist push has arrived after a bruising stretch for investors, with the share price down sharply year to date, even after a 16.1 percent 1 month share price return that hints at stabilizing sentiment and potential re rating if...

If you are wondering whether Essent Group is still a smart buy after its strong run, you are not alone. This piece will walk through what the current share price really implies about value. The stock has climbed 2.9% over the last week, 8.5% over the past month, and is now up 27.0% over the last year, building on an impressive 80.9% gain over three years and 66.6% over five years. Investors have been responding to a steady stream of positive housing and mortgage market data, which has...

Investor anxiety over a potential AI bubble has dragged Zeta Global Holdings (ZETA) into the latest tech selloff, as warnings about shrinking margins push traders to rotate from high growth software names into steadier corners of the market. See our latest analysis for Zeta Global Holdings. Even with the recent AI jitters weighing on sentiment, Zeta’s latest close at $17.99 leaves it with a mildly negative year to date share price return. Its three year total shareholder return of 119.12...

Celldex Therapeutics (CLDX) has been back on traders radar after a recent bump in the share price, leaving many investors wondering whether this clinical stage biotech is quietly setting up for its next move. See our latest analysis for Celldex Therapeutics. With the latest uptick to about $25.60, Celldex’s 30 day share price return of 2.73 percent and modest 90 day gain hint at cautiously improving momentum, even as the 3 year total shareholder return of negative 41.96 percent reminds...

Flowserve (FLS) has quietly rewarded patient shareholders, with the stock up about 24% over the past year and roughly 25% in the past 3 months, outpacing many industrial peers. See our latest analysis for Flowserve. With the share price now around $71, Flowserve has built steady momentum, with a strong 90 day share price return and a standout three year total shareholder return that point to rising confidence in its long term prospects. If Flowserve’s run has you rethinking your watchlist,...

The Trade Desk (TTD) just announced a small round of layoffs, trimming less than 1% of its staff, a follow up to last year's larger restructuring as the ad tech environment continues to tighten. See our latest analysis for Trade Desk. Those small cuts sit against a much tougher backdrop, with the 1 year share price return down around 70 percent as investors reassess growth and competitive risks, even though Trade Desk is still growing revenue and margins. As a result, sentiment looks more...

Wondering if Match Group at around $33 is a hidden bargain or a value trap in the making? This article will walk you through the numbers in plain language so you can decide for yourself. Despite a modest 4.8% gain over the last 30 days and being up 1.3% year to date, the stock is still roughly flat over the past year and sits far below its 5 year highs. That keeps both value hunters and skeptics interested. Recent headlines have focused on Match Group sharpening its product strategy and...

Leidos Holdings has appointed Theodore "Ted" Tanner Jr. as its new chief technology officer, effective January 5, 2026, bringing experience from BigBear.ai, IBM Watson Health, and several AI-focused startups, while outgoing CTO Jim Carlini will remain as a senior advisor on national security. Tanner’s background in artificial intelligence, machine learning, and cloud technologies, underscored by 18 U.S. patents and work across defense and healthcare, signals a deeper push by Leidos into...

KB Home (KBH) has wrapped up FY 2025 with fourth quarter revenue of about $1.7 billion and basic EPS of roughly $1.59, setting a clear marker for how its homebuilding cycle is playing out amid softer profitability trends over the past year. The company has seen quarterly revenue ease from around $2.0 billion and EPS of about $2.59 in Q4 2024 to $1.7 billion and $1.59 in Q4 2025, while trailing net profit margins have compressed. This puts the spotlight firmly on how sustainable its current...

Iovance Biotherapeutics (IOVA) is back in the spotlight after fresh FDA related progress on its lifileucel cancer therapy and a Phase 2 melanoma update. These developments are reshaping how investors are sizing up the stock. See our latest analysis for Iovance Biotherapeutics. Those FDA tailwinds and trial updates have sparked a sharp turnaround in sentiment. The latest share price of $2.48 is supported by a 7 day share price return of 12.73 percent and a 90 day share price return of 20.98...

United Therapeutics (UTHR) has been drawing fresh attention after progress in its xenotransplantation studies and stronger financial results, a combination that is quietly reshaping how many investors frame the long term story. See our latest analysis for United Therapeutics. Those xenotransplantation milestones and solid earnings have coincided with a powerful move in the stock, with a year to date share price return above 40 percent and five year total shareholder return above 200 percent,...